Ashvattha Therapeutics to Present Late-Breaking Phase 2 DME and nAMD Data at 25th EURETINA Congress
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration represents a potential paradigm shift from frequent in-office intravitreal injections Chief Medical Officer also to present at the Ophthalmology Futures Forums: Retina Forum 2025 REDWOOD CITY, Calif., August 26, … Read more